Nicole Onetto
Director/Board Member at BOLT BIOTHERAPEUTICS, INC.
Net worth: 31 741 $ as of 2024-04-29
Profile
Nicole M.
Onetto is an Independent Non-Executive Director at Basilea Pharmaceutica AG, an Independent Director at Bolt Biotherapeutics, Inc., and a Director at CDR-Life Inc. She previously held positions at Bristol Myers Squibb Co., ImmunoGen, Inc., YM BioSciences, Inc., Sierra Oncology, Inc., Sunesis Pharmaceuticals, Inc., Ontario Institute for Cancer Research, NBE-Therapeutics AG, Viracta Therapeutics, Inc., Gilead Sciences, Inc., OSI Pharmaceuticals, Inc., NeXstar Pharmaceuticals, Inc., and ZymoGenetics, Inc. She has also earned graduate and undergraduate degrees from the University of Montréal and a doctorate from Université de Paris 5 René Descartes.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
BASILEA PHARMACEUTICA AG
0.01% | 2022-12-30 | 737 ( 0.01% ) | 31 741 $ | 2024-04-29 |
2023-04-18 | 0 ( -.--% ) | - $ | 2024-04-29 | |
2023-06-11 | 0 ( -.--% ) | - $ | 2024-04-29 |
Nicole Onetto active positions
Companies | Position | Start |
---|---|---|
BASILEA PHARMACEUTICA AG | Director/Board Member | 2017-04-26 |
BOLT BIOTHERAPEUTICS, INC. | Director/Board Member | 2021-12-13 |
Former positions of Nicole Onetto
Companies | Position | End |
---|---|---|
VIRACTA THERAPEUTICS, INC. | Director/Board Member | 2023-06-07 |
VIRACTA THERAPEUTICS, INC. | Director/Board Member | 2021-01-31 |
SIERRA ONCOLOGY, INC. | Director/Board Member | 2019-11-21 |
IMMUNOGEN, INC. | Director/Board Member | 2016-12-08 |
Training of Nicole Onetto
University of Montréal | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 6 |
---|---|
IMMUNOGEN, INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
GILEAD SCIENCES, INC. | Health Technology |
BASILEA PHARMACEUTICA AG | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
BOLT BIOTHERAPEUTICS, INC. | Health Technology |
Private companies | 8 |
---|---|
OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Ontario Institute for Cancer Research
Ontario Institute for Cancer Research Hospital/Nursing ManagementHealth Services Ontario Institute for Cancer Research provides research on the prevention, early detection, diagnosis, and treatment of cancer. It offers Innovation programs, like cancer stem cell, innovation in target validation, and smarter imaging, Technology programs, like drug discovery, genome technologies, informatics and bio-computing, imaging translation, and tranformative pathology, and Translation programs. The company was founded by Calvin R. Stiller in December 2005 and is headquartered in Toronto, Canada. | Health Services |
Université de Paris 5 René Descartes | Consumer Services |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Nicole Onetto